KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Biogen (BIIB) Accumulated Depreciation & Amortization (2016 - 2025)

Biogen has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $779.9 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $779.9 million for Q4 2025, up 15.85% from a year ago — trailing twelve months through Dec 2025 was $779.9 million (up 15.85% YoY), and the annual figure for FY2025 was $779.9 million, up 15.85%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $779.9 million at Biogen, up from $579.7 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for BIIB hit a ceiling of $779.9 million in Q4 2025 and a floor of $102.6 million in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $353.8 million (2021), compared with a mean of $361.5 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 39.47% in 2022 and later decreased 21.52% in 2023.
  • Biogen's Accumulated Depreciation & Amortization stood at $487.7 million in 2021, then grew by 6.29% to $518.4 million in 2022, then fell by 4.55% to $494.8 million in 2023, then soared by 36.05% to $673.2 million in 2024, then grew by 15.85% to $779.9 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $779.9 million (Q4 2025), $579.7 million (Q3 2025), and $377.5 million (Q2 2025) per Business Quant data.